Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06853912 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06853912 · ClinicalTrials.gov record · last posted 2026-08-13

PsiloStudy: Psilocybin With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring PTSD & Alcohol Use Disorder (AUD)

Study acronym: Psi-PS
StatusActive, Not Recruiting
PhasePhase 2
Started2025-06-01
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This study is a phase 2 single-site, double-blind, placebo-controlled, randomized clinical trial with an open-label extension phase to examine the safety of psilocybin (25 mg) combined with psychological support (Psi-PS) for treatment of approximately 40 military veterans and first responders (ages 21-65) with co-occurring alcohol use disorder (AUD) and posttraumatic stress disorder (PTSD). Psychological support is defined as providing safety, reassurance, active listening, and empathetic presence during the drug administration session in a nondirective manner. We hypothesize that Psi-PS may provide a safe treatment for participants. The primary objective of study is to characterize the safety of psilocybin combined with psychological support (Psi-PS) for individuals with co-occurring alcohol use disorder (AUD) and PTSD.

Protocol amendment history 3 changes detected by DataLookout

2026-08-14
notable
Enrollment closed, study ongoing
2026-08-14
notable
Primary completion pushed: 2026-06-01 → 2026-11-01
2026-08-14
minor
Completion pushed: 2026-06-01 → 2027-06-01
Trial Details
NCT Number NCT06853912
Lead Sponsor Nathan Brashares Sackett
Collaborators: Washington State Legislation
Conditions Alcohol Use Disorder (AUD), PTSD
Enrollment 40 participants
Start Date 2025-06-01
Primary Completion 2026-11-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-13